FDA Rebif Decision Expected In March, Serono Says
Serono has "a big inventory" of the multiple sclerosis therapy Rebif (interferon beta-1a) in anticipation of a spring launch, CFO Jacques Theurillat said during a quarterly earnings call Feb. 13
Serono has "a big inventory" of the multiple sclerosis therapy Rebif (interferon beta-1a) in anticipation of a spring launch, CFO Jacques Theurillat said during a quarterly earnings call Feb. 13